Lyfgenia or Casgevy: Who Will Lead the Sickle Cell Disease Treatment Space?

Hematological Disorders

AstraZeneca’s Ultomiris; HebaBiz’s ...

AstraZeneca's Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral Sclerosis AstraZeneca's 39 billion USD complete acqui...

Aug 24, 2021

fecal-incontinence-market
Fecal Incontinence Therapeutics Market Surges with Innovative Therapies in the Pipeline

Fecal Incontinence (FI) is a condition in which individuals lose the control of bowel movements leading to unexpected, involuntary leakage of stools. Also known as Bowel Incontinence, it is a result of constipation, diarrhea, and nerve damage due to aging. The condition can be of two types: urge incontinence, where...

Find More
Latest-pharma-happenings-for-rallybio-sanofi-eureka-lilly-unity-biotechnology
Unity’s advanced vascular eye disease trial; Rallybio raises $100 M; Sanofi bets over $1B for Eureka’s candidate; Lilly invests in MiNA;

UNITY Biotechnology declares positive data from phase 1 clinical trial of UBX1325 in Advanced Vascular Eye Disease patients  UNITY Biotechnology, Inc., a biotechnology company developing therapeutics to decrease, impede, or reverse diseases of aging, declared positive data from its Phase 1 safety study of U...

Find More
Benefits-advantage-Disadvantages-pros-and-cons-of-wearable-health-devices-technologies
Wearable Devices: Weighing the Potential Benefits and Pitfalls of the Innovative Wearable Products

Wearables are electronic devices that are worn on the body part to track, analyze and transmit real-time personal data of the health or workout. The wearables come in different forms and sizes and some of the most common devices include a fitness tracker, headbands, posture monitors, wearable patches, smart glasses...

Find More

More Views & Analysis

recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos
InnoCare’s Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab

InnoCare Receives Go-ahead for Clinical Trial of TYK2 Inhibitor ICP-332 in China InnoCare, a biopharma firm developing novel therapies for the treatment of cancer and autoimmune diseases, today announced the approval of Phase I clinical trial of its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, by the China...

Find More

COVID-19-Vaccines-Hemophilia-B-uniQure-Gene-Therapy-J-J-Covid-Vaccine-Covaxin
Ocugen-Bharat Biotech’s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal

Ocugen-Bharat Biotech’s Covaxin Shows Efficacy Against B.1.617 Variant With the COVID-19 cases exponentially increasing, there is a worrisome climate all over the world. Physicians, doctors, researchers, the whole healthcare and pharmaceutical industry are at their toes fighting the second wave of the coronaviru...

Find More

recent-pharma-biotech-lifescience-healthcare-news-updates-for-vertex-virta-kalvista-ovid-crispr-therapeutics
Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M

Vertex leads in CRISPR Therapeutics partnership with USD 900 Million upfront Vertex has boosted a deal with CRISPR Therapeutics to USD 900 million upfront as the companies compete against bluebird bio to the market with a novel gene-editing therapy for sickle cell disease and beta-thalassemia called CTX001. B...

Find More

recent-pharma-biotech-news-updates-for-cidara-jj-supernus-rain
Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application

Cidara Therapeutics Inks USD 780M Deal with J&J The share price of Cidara observed a sudden jump after the news of the collaboration of the company with J&J came. Cidara Therapeutics has announced a deal with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 to prevent and treat...

Find More

chimeric-antigen-receptor-therapies-in-blood-cancers
A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers

Chimeric Antigen Receptor (CAR) Therapies have changed the treatment paradigm of hematological malignancies to a vast extent. These personalized therapies have not only evolved as a game-changer in the field of medicine but also in the lives of the patients. Until the last approvals made by Novartis and Kite Pha...

Find More

recent-pharma-news-update-happenings-for-amgen-rodeo-novartis-organon-alydia-forma
Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels

Amgen to acquire Rodeo Therapeutics for USD 55 Million Upfront  Amgen Inc. and Rodeo Therapeutics Corporation announced a deal under which Amgen will take over Rodeo, a privately-held biopharmaceutical company based in Seattle, which develops small-molecule therapies to enhance regeneration and repair of se...

Find More

Peanut Allergy accounts for the majority of severe food-associated allergic reactions. It is strictl.....

Find More

Interoperability refers to the ability of electronic health records (EHRs) and other healthcare data.....

Find More

Spinal Cord Injury (SCI) causes extreme back pain and at times triggers an “accelerating aging” .....

Find More

Gout is a chronic disease caused by the deposition of monosodium urate (MSU) crystals in joints. It .....

Find More

Wearable technology has been gaining momentum for the last few years as an effect of the fourth indu.....

Find More

In the present scenario, the 3-D printing and bioprinting technology in the medical devices industry.....

Find More